Gene · 3776
KCNK2: potassium two pore domain channel subfamily K member 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. KCNK2: potassium two pore domain channel subfamily K member 2. Genes, record 3776. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3776
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| O95069 | Potassium channel subfamily K member 2 | 426 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents14
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 58589 | O95069 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 12616 | O95069 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 13937 | O95069 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 2243 | O95069 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 2243 | O95069 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 13937 | O95069 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 12616 | O95069 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 65712 | O95069 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 644 | O95069 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 168683 | O95069 | Espacenet |
1 to 10 of 14
See all 14 patentsDrugs5
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| DESFLURANE | CHEMBL1200733 | Potassium channel subfamily K member 2 opener | OPENER | ChEMBL |
| ENFLURANE | CHEMBL1257 | Potassium channel subfamily K member 2 opener | OPENER | ChEMBL |
| HALOTHANE | CHEMBL931 | Potassium channel subfamily K member 2 opener | OPENER | ChEMBL |
| ISOFLURANE | CHEMBL1256 | Potassium channel subfamily K member 2 opener | OPENER | ChEMBL |
| SEVOFLURANE | CHEMBL1200694 | Potassium channel subfamily K member 2 opener | OPENER | ChEMBL |
Trials168
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07602400 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07568938 | DESFLURANE | ClinicalTrials.gov | ||
| NCT07513870 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07457593 | ISOFLURANE | ClinicalTrials.gov | ||
| NCT07440758 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07440758 | DESFLURANE | ClinicalTrials.gov | ||
| NCT07338578 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07313969 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07304206 | SEVOFLURANE | ClinicalTrials.gov | ||
| NCT07271472 | DESFLURANE | ClinicalTrials.gov |
1 to 10 of 168
See all 168 trialsNIH grants863
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | KCNK2 papers | Newest fiscal year |
|---|---|---|---|
| R01MH093603 | Genetic and chemical biological studies of K2P structure, function, andmodulation | 12 | 2025 |
| P30EY014800 | University of Utah Core Vision Research Grant | 7 | 2025 |
| R01EY027920 | Molecular mechanisms of mechanotransduction in the aqueous outflow pathway | 7 | 2025 |
| P30EY014801 | Miami Center for Vision Research | 5 | 2025 |
| T32EY024234 | Vision Research Training Grant at the University of Utah | 4 | 2025 |
| P30EY005722 | Center Core Grant for Vision Research | 3 | 2025 |
| R01HL059949 | Structural Determinants of PIP2 Regulation | 3 | 2025 |
| K12HD047349 | Pediatric Critical Care and Trauma Scientist Development Program (PCCTSDP) | 2 | 2025 |
| P30EY003176 | UC Berkeley Vision Science CORE | 2 | 2025 |
| P30EY008126 | Core Grant in Vision Research | 2 | 2025 |
1 to 10 of 863Source NIH's project files
See all 863 nih grantsPapers1,439
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A hypothalamic neuronal population coordinates metabolic adaptations to cold. | Neuron | 2026 | 42790426 | PubTator, text mining | PubMed |
| A conserved conformation-dependent mechanism for the TREK two-pore domain potassium channel inhibitors carvedilol and fluphenazine. | Mol Pharmacol | 2026 | 42772120 | PubTator, text mining | PubMed |
| K2P channels as emerging therapeutic targets for pain: insights from functional studies and transcriptomic analyses. | Front Pharmacol | 2026 | 42756049 | PubTator, text mining | PubMed |
| Magnetic nanoparticle formulations to activate TREK and Piezo mechanosensitive ion channels (MICA) for enhanced osteogenesis. | Regen Biomater | 2026 | 42636326 | PubTator, text mining | PubMed |
| A TREK that activates thermogenic adipose tissue by sensing cold air in the lung. | Dev Cell | 2026 | 42586049 | PubTator, text mining | PubMed |
| Mosapride promotes internalization of a TREK1-HTR4 complex and exerts rapid antidepressant-like effects. | Mol Psychiatry | 2026 | 42542439 | PubTator, text mining | PubMed |
| Mechanosensitive ion channels in immunity from biophysics to mechanomedicine. | Biophys J | 2026 | 42522197 | PubTator, text mining | PubMed |
| Disentangling Sex Differences in Sulfonylurea Drug Response With Genome-Wide Association Studies in Individuals With Type 2 Diabetes. | Clin Pharmacol Ther | 2026 | 42504935 | PubTator, text mining | PubMed |
| A TREK-1/AQP4/TRPA1/BDNF Signaling Axis Is Associated With Astrocytic Volume Transients, Synaptic Plasticity, and Spatial Memory. | Glia | 2026 | 42458823 | PubTator, text mining | PubMed |
| Ionic Homeostasis Failure in Major Depressive Disorder: Ion Channel Mechanisms, Excitation-Inhibition Imbalance, and Precision Therapeutics. | Int J Mol Sci | 2026 | 42450349 | PubTator, text mining | PubMed |
1 to 10 of 1,439
See all 1,439 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3776
GET https://conductscience.org/api/genes/v1/3776/patents